Clinical Trial Update: SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial at Peking University First Hospital is evaluating SABR radiation combined with axitinib and toripalimab for recurrent or metastatic ren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Peking University First Hospital | Conditions: Radiation Therapy, Targeted Therapy | Phase 2 | Status: RECRUITING